65,437 trials
Nasal Carriers of Staphylococcus Aureus
Primary: Carrier Rate for Staphylococcus Aureus — 20.8 percentage of subjects
Hyperglycemias
Primary: Time in the Glycaemic Target Range (5.5-7.0 mmol/l) During the Period of Observation of 48 Hours — 13.0; 22.5 hours
Dental Caries
Primary: Number of Caries Incident Cases — 42; 23; 14 participants — p=<0.001
Type 2 Diabetes Mellitus
Primary: Recovery Time (Rt[65] From Insulin-induced Hypoglycemia — 103; 71 minutes — p=0.005
End Stage Renal Disease (ESRD)
Primary: Incidence of All Biopsy Proven Acute Rejection. — 1; 4 Participants
Trachoma · Chlamydia Trachomatis
Primary: Infection With Chlamydia Trachomatis Diagnosed by Use of NAATs [Nucleic Acid Amplification Test] — 57; 42; 5; 3 Participants
Leukemia
Primary: Number of Confirmed Responses (Complete or Partial Response Noted as the Objective Status for a Duration of at Least 2 Months) at 6 Months — 31 Participants
Migraine, Acute
Primary: Pain Freedom at 2 Hours Post Dose in Participants Between 12 and 17 Years of Age — 87; 63; 197; 223 participants — p=0.025
Alzheimer's Disease
Primary: Sensitivity Analysis in All Autopsy Population — 36; 3 participants
Chronic Obstructive Pulmonary Disease
Primary: Exercise Endurance Time During a Sub-maximal Constant-load Cycle Ergometry Test (SMETT) After 3 Weeks (Day 21) of Treatment — 505.63; 416.70 seconds
Healthy
Primary: Area Under the Curve From Time Zero to 72 Hours [AUC (0-72)] — 419.9; 442.1 nanogram hour per milliliter (ng*h/mL)
Alzheimer's Disease
Primary: Correlation of Florbetapir-PET Image and Amyloid Plaque Density — 0.78 Correlation coefficient — p=<0.0001
Depression · Depressive Disorder · Depressive Disorder, Major
Primary: Change in Hamilton Psychiatric Rating Scale for Depression (HAM-D17) Score From Baseline to Week 8. — -12.64; -8.33 units on scale — p=<0.001
Leukemia
Primary: Progression-free Survival (PFS) — 4.3; 14.5 Months
Facial Wrinkles
Primary: Full Face Global Aesthetic Improvement — 2.5 units on a scale